Search our science

Search our scientific publications and resources
on rare bleeding disorders

Molecule
Study Phase
Content Type


Scientific resources from Novo Nordisk

Novo Nordisk supports sharing of the scientific research on our molecules. The search results below include peer-reviewed articles that are authored by Novo Nordisk employees or are funded by Novo Nordisk, as well as congress abstracts, posters and presentations, and also related educational resources.

 

Search Results

We found 383 resources matching your search criteria

Audio poster
Brian Lauritzen, Mads Bjelke, Marie Rossen, Mikala Skydsgaard, Marianne Kjalke, Olle Björkdahl, Stine L Kjellev; A Novel Next-Generation FVIII Mimetic, Mim8, Has a Favourable Safety Profile. Results from a 26-Week Safety Study in Cynomolgus Monkeys. Blood 2020; 136 (Supplement 1): 26–27. doi: https://doi.org/10.1182/blood-2020-137006
Abstract
Vance MacDonald, Xin Ying Lee, Alexandre Caillaud, Maria Luckevich, Anthony Bentley; Estimation of the Impact on Treatment Costs of a Switch to Nonacog Beta Pegol (N9-GP) for the Treatment of Adults with Hemophilia B in Canada Based on Real-World Factor IX (FIX) Consumption and Clinical Outcomes Pre- and Post-Switch. Blood 2020; 136 (Supplement 1): 19. doi: https://doi.org/10.1182/blood-2020-134236
Abstract
Amy D Shapiro, Giancarlo Castaman, Katarina Cepo, Sidsel Marie Tønder, Tadashi Matsushita, Lone Hvitfeldt Poulsen, Guy Young, Silva Zupancic-Šalek, Victor Jimenez Yuste; Safety and Longer-Term Efficacy of Concizumab Prophylaxis in Patients with Hemophilia a or b with Inhibitors: Results from the Extension Part of the Phase 2 explorer4 Trial. Blood 2020; 136 (Supplement 1): 40–41. doi: https://doi.org/10.1182/blood-2020-139910
Abstract

Brian Lauritzen, Mads Bjelke, Marie Rossen, Mikala Skydsgaard, Marianne Kjalke, Olle Björkdahl, Stine L Kjellev; A Novel Next-Generation FVIII Mimetic, Mim8, Has a Favourable Safety Profile. Results from a 26-Week Safety Study in Cynomolgus Monkeys. Blood 2020; 136 (Supplement 1): 26–27. doi: https://doi.org/10.1182/blood-2020-137006

Poster
Giangrande P, Lee XY, Curry N, Benchikh El Fegoun S. Prophylaxis with Turoctocog Alfa Pegol (N8-GP) Maintains Improvements in Health-Related Quality of Life (HRQoL) and Treatment Satisfaction (TS) over ?4.5 Years in Patients with Haemophilia A (HA) [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1).
Audio poster
Matino D, Iorio A, Keepanasseril A, Germini F, Birkegård AC, Caillaud A, Carcao M, Hews-Girard J, Iserman E, James P, Lee A, Phua C, Sun H, Teitel J, Poon M-. A Canadian, Multi-Center, Retrospective, Non-Interventional Study of Clinical Outcomes from Early Use of N9-GP Compared with Previous Treatment in Patients with Hemophilia B in a Real-World Setting [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1)
Audio poster
Lund J, Østergaard H, Greisen PJ, Bonde AC, Gandhi PS, Lorenzen N, Johansson E, Andersen LM, Rasch MG, Lund S, Zhou R, Bjelke JR, Røder G, Johnsen LB, Stavenuiter F, Egebjerg T, Henriksen A, Hansen BG, Thorn K, Hilden I. A Novel FVIIIa-Mimetic Bispecific Antibody, Mim8, Enhances FIXa Proteolytic Activity While Allowing for Efficient, Lipid-Dependent Assembly with FX [abstract]. Res Pract Thromb Haemost. 2020; 4 (Suppl 1)

This website is intended
for healthcare professionals (HCPs)
outside of the U.S.

Take me to www.novonordisk.com